[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369699-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369699-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","experimental-and-clinical-tests-of-fda-approved-kinase-inhibitors-for-the-treatment-of-neurological-disorders-update-2024","Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders - (update 2024)","","Since the prior summary of 74 FDA-approved kinase inhibitors studied in clinical and preclinical trials for non-cancerous neurological treatment, the US FDA approved 13 additional kinase inhibitors from early 2022 onward. This update compiles new evidence for the expanded set of 87 FDA-approved kinase inhibitors evaluated for non-cancerous neurological disorders. By October 2024, most have been tested in animal models, while 20 entered clinical trials and six were used off-label in humans.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/experimental-and-clinical-tests-of-fda-approved-kinase-inhibitors-for-the-treatment-of-neurological-disorders-update-2024/369699/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/experimental-and-clinical-tests-of-fda-approved-kinase-inhibitors-for-the-treatment-of-neurological-disorders-update-2024/369699.png","ImageObject",300,407,{"name":42,"@type":43},"Adam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the document update cover about FDA-approved kinase inhibitors?","Question",{"text":63,"@type":64},"It updates evidence for 87 FDA-approved kinase inhibitors evaluated for non-cancerous neurological disorders, including those approved after early 2022.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many of the FDA-approved kinase inhibitors had been tested or entered studies by October 2024?",{"text":68,"@type":64},"By October 2024, nearly all 87 had been tested in animal models; 20 had entered clinical trials and six were used off-label in humans.",{"name":70,"@type":61,"acceptedAnswer":71},"Why might some kinase inhibitors be less effective for treating neurological disorders?",{"text":72,"@type":64},"The document highlights intellectual property and legal considerations and limited blood-brain barrier (BBB) permeability that may restrict central nervous system targeting.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369699,1790327343,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":104,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":97,"preview_urls":146},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Explor Drug Sci. Author manuscript; available in PMC 2025 July 24. |\n| --- | --- |\n\nPublished in final edited form as:  \nExplor Drug Sci. 2025 ; 3: . doi:10.37349/eds.2025.1008116 .  \nExperimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024)  \nHassan Aliashrafzadeh 1 , Dewey Liu 1 , Samantha De Alba 1 , Imad Akbar2 , Austin Lui 1 , Jordan Vanleuven 1 , Ryan Martin 1,3 , Zhang Wang4,5 , Da Zhi Liu 1,6,*  \n1 Department of Neurology, University of California, Davis, CA 95616, USA  \n2Ayub Medical College, Abbottabad 22020, Pakistan  \n3 Department of Neurological Surgery, University of California, Davis, CA 95616, USA  \n4 Institute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616, USA  \n5 Department of Chemistry, University of California, Davis, CA 95616, USA  \n6Mirnova Therapeutics, Inc. , Davis, CA 95618, USA  \nAbstract  \nSince our previous summary of the 74 FDA-approved kinase inhibitors in clinical and preclinical trials for non-cancerous neurological treatment, the US FDA has approved 13 additional kinase inhibitors since early 2022. This update incorporates new evidence for the now 87 FDA-approved kinase inhibitors in clinical and preclinical trials for the treatment of non-cancerous neurological disorders. By the end of October 2024, nearly all 87 FDA-approved kinase inhibitors have been tested in various animal models of non-cancerous neurological disorders, with twenty entered into clinical trials and six used for off-label treatments of neurological conditions in humans.  \nConsidering the challenges posed by intellectual property (IP), legal considerations, and limited blood-brain barrier (BBB) permeability, which may restrict some FDA-approved kinase inhibitors from effectively targeting the central nervous system (CNS), we further discuss the feasibility of  \nThis is an Open Access article licensed under a Creative Commons Attribution 4.0 International License ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.  \n*Correspondence: Da Zhi Liu, Mirnova Therapeutics, Inc., Davis, CA 95618, [USA. djliu@mirnovatherapeutics.com](USA. djliu@mirnovatherapeutics.com). Author contributions  \nHA, DL, SDA, IA, AL, JV, RM, and ZW: Writing—review & editing. DZL Conceptualization, Writing—review & editing, Funding acquisition. All authors have read and agreed to the published version of the manuscript.  \nConflicts of interest  \nDa Zhi Liu who is the Editorial Board Member of Exploration of Drug Science and Guest Editor of Leveraging the FDA-Approved Kinase Inhibitors to Treat Neurological Disorders had no involvement in the decision-making or the review process of this manuscript. The other authors declare no conflicts of interest.  \nEthical approval Not applicable.  \nConsent to participate Not applicable.  \nConsent to publication Not applicable.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nAliashrafzadeh et al. Page 2  \ndesigning novel proprietary analogs with enhanced BBB penetration to improve their therapeutic potential in neurological disorders. The new drugs typically retain full IP rights and remain costly; while repurposing kinase inhibitors may provide effective and affordable treatments for non-cancerous neurological disorders.  \nKeywords  \nKinase inhibitors; aberrant cell cycle; clinical trials; preclinical experiments; neurological  \ndisorders  \nIntroduction  \nWe developed an original concept of“","cbCaisdCe4SBXuey","https://ap.wps.com/l/cbCaisdCe4SBXuey","pdf",532239,"English","# Abstract\n# Introduction\n## Aberrant Cell Cycle Disease (ACCD) concept\n## FDA-approved kinase inhibitor landscape and update scope\n## Challenges for repurposing to the CNS","[{\"question\":\"What does the document update cover about FDA-approved kinase inhibitors?\",\"answer\":\"It updates evidence for 87 FDA-approved kinase inhibitors evaluated for non-cancerous neurological disorders, including those approved after early 2022.\"},{\"question\":\"How many of the FDA-approved kinase inhibitors had been tested or entered studies by October 2024?\",\"answer\":\"By October 2024, nearly all 87 had been tested in animal models; 20 had entered clinical trials and six were used off-label in humans.\"},{\"question\":\"Why might some kinase inhibitors be less effective for treating neurological disorders?\",\"answer\":\"The document highlights intellectual property and legal considerations and limited blood-brain barrier (BBB) permeability that may restrict central nervous system targeting.\"}]","Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders - (update 2024) | PDF",1790184147,126,[147,151,155,159,163],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fecb3d91ee2428004dfb0d4338792a70.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8a84beea0568205d7b7437115d2b736.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d164542bbbf9b097b17957167a14fce4.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/040559e0ade3750a70bbcdc25fd9c063.webp",980,1268,{"page_no":97,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/186602168d6411f98395c404de097834.webp",979,1267]